Study identifier:D5161R00045
ClinicalTrials.gov identifier:NCT06039683
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicountry, Multicentre, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after First Line Osimertinib in patients with advanced and Metastatic NSCLC EGFRm in the GCC Region
Carcinoma, Non-Small-Cell Lung
Phase 4
No
-
All
54
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|